GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

semaglutide or tirzepatide

Company
Mayo Clinic
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
11 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

11 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for semaglutide or tirzepatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06374875

    Fibrosis Lessens After Metabolic Surgery

    Not yet reported The Cleveland Clinic 120 participants Est. completion 2029-12-31 22 sites
    MASLDMASH Other conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, Obesity
    View official trial listing →
  • Recruiting NCT NCT06575738

    Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents

    Not yet reported University of Colorado, Denver 40 participants Est. completion 2027-10-01 1 site Added to GLP-1
    Other conditions: Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
    View official trial listing →
  • Recruiting NCT NCT06790160

    Study of Patients Being Treated With Anti-obesity Medication

    Texas Tech University 100 participants Est. completion 2027-12 1 site
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Recruiting NCT NCT06897475

    A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Not yet reported Eli Lilly and Company 240 participants Est. completion 2027-01 60 sites
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07042672

    Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

    Haukeland University Hospital 80 participants Est. completion 2028-12-31 1 site
    Other conditions: Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge, Eating Disorders, GLP-1, CBT, Obesity &Amp; Overweight
    View official trial listing →
  • Recruiting NCT NCT07202247

    Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

    Not yet reported City of Hope Medical Center 60 participants Est. completion 2028-04-09 1 site Added to GLP-1
    Other conditions: Prostate Carcinoma, Recurrent Prostate Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07213323

    Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment

    Not yet reported Hospices Civils de Lyon 50 participants Est. completion 2028-08-05 1 site Stand-alone
    Other conditions: Obesity &Amp; Overweight, Digestive Disorders
    View official trial listing →
  • Recruiting NCT NCT07223242

    Tailored Exercise Training Study Among Adults With HFpEF

    Not yet reported, Not yet reported University of Texas Southwestern Medical Center 120 participants Est. completion 2026-12-30 1 site Stand-alone
    Heart failure Other conditions: Diabetic Cardiomyopathies
    View official trial listing →
  • Recruiting NCT NCT07229170

    Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients

    San Raffaele Telematic University 150 participants Est. completion 2028-01-01 4 sites Stand-alone
    Other conditions: Obesity & Overweight, Taste Alterations, Weight Loss, Eating Behavior Changes
    View official trial listing →
  • Recruiting NCT NCT07653412

    Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

    National and Kapodistrian University of Athens 220 participants Est. completion 2027-06-30 1 site
    Other conditions: Obesity (Disorder), Anti-obesity Agents, Precision Medicine
    View official trial listing →
  • Recruiting NCT NCT07740291

    Tirzepatide Impact Assessment Study

    Not yet reported Texas Tech University 27 participants Est. completion 2026-12-07 1 site Stand-alone
    Other conditions: Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
    View official trial listing →
  • Completed NCT NCT06640972

    Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

    Not yet reported Response Pharmaceuticals 68 participants Est. completion 2025-05-13 1 site
    Other conditions: Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
    View official trial listing →
  • Not yet recruiting NCT NCT06856928

    Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.

    University of Colorado, Denver 16 participants Est. completion 2027-12
    Other conditions: Obesity; Drug
    View official trial listing →
  • Enrolling by invitation NCT NCT07041983

    24-h Energy Expenditure and Anti-obesity Medication

    University of Pisa 30 participants Est. completion 2026-12-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Enrolling by invitation NCT NCT07057310

    Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

    Not yet reported Mayo Clinic 30 participants Est. completion 2027-03-31 1 site Added to GLP-1
    Other conditions: Obesity, Menopause
    View official trial listing →
  • Not yet recruiting NCT NCT07156331

    Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes

    Kristin Clemens 20 participants Est. completion 2027-12-31
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT07417618

    INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

    Brigham and Women's Hospital 60000 participants Est. completion 2026-06-19 1 site
    Type 2 diabetesCardiovascular disease Other conditions: Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07444073

    Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock

    National University of Singapore 440 participants Est. completion 2027-12-31 2 sites
    Other conditions: Aging, Obesity & Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07728812

    Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy

    Not yet reported Phenomix Sciences 424 participants Est. completion 2029-01-01 Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.